The 2026 Beard Minoxidil Trial: What It Actually Showed

For about ten years, essentially every claim made about minoxidil and beard growth traced back to a single study: a 2016 Thai trial of 48 men. That study was decent, but it was small, it ran 16 weeks, and its primary outcome was a panel of physicians scoring before-and-after photographs. An enormous amount of internet confidence was built on a fairly narrow base.

That base just got wider. A new randomized, double-blind, placebo-controlled trial from Ramathibodi Hospital at Mahidol University has been published in the Journal of Dermatological Treatment, and it is methodologically the best facial-hair minoxidil study we have. It is also easy to misread, because of who it enrolled.

What the trial did

Sixty-nine transgender men, all already on stable gender-affirming hormone therapy, were randomized one-to-one to receive either topical 3% minoxidil or a matched vehicle placebo. Both groups applied 0.2 mL twice daily for twelve weeks. The design was rigorous in ways that matter: randomization was computer-generated by an independent statistician, allocation was concealed in sequentially numbered opaque envelopes held by the hospital pharmacy, and the study solutions were prepared in identical containers labeled only with participant numbers. Participants, investigators, outcome assessors, and data analysts all stayed blinded until the final analysis.

The primary outcomes were changes in hair density and hair diameter, measured by videodermoscopy rather than by eye. That is the important upgrade over 2016. Photographic scoring by a physician panel is subjective and coarse; videodermoscopy counts hairs per square centimeter and measures shaft thickness in micrometers. Secondary outcomes covered the modified Ferriman–Gallwey score, the Dermatology Life Quality Index, and patient satisfaction.

The numbers

Two things stand out. First, the placebo group essentially did not move — beard density changed by 0.08 hairs per square centimeter, which is noise. That is a cleaner separation than most dermatology trials produce, and it means the effect is very unlikely to be regression to the mean or measurement drift.

Second, density and diameter both moved. This is the mechanistic point people miss. Minoxidil is not only recruiting additional follicles into an active growth phase; the hairs that do grow are coming in measurably thicker. Diameter gains are what produce the visual impression of a fuller beard, because coverage scales with shaft cross-section, not with hair count alone. A modest density gain paired with a real diameter gain looks far better in a mirror than the raw numbers suggest.

Third — and this is genuinely useful if you are deciding where to apply — the mustache area responded noticeably more strongly than the beard area on both measures. That is consistent with what the mid-face region does under androgen exposure generally, and it argues against treating the whole face as one uniform target.

The part that gets misreported

This trial studied transgender men on gender-affirming hormone therapy. Every participant was receiving exogenous testosterone at a stable dose. That is not a footnote; it is the context in which the drug was tested.

Why it matters: facial hair development is androgen-driven. Testosterone is converted to dihydrotestosterone in the skin, and DHT is what pushes facial vellus follicles toward terminal hair. In this population, that androgen signal had been switched on relatively recently and the follicles had not yet completed the transition. Minoxidil, which works through a different pathway — it lengthens the anagen growth phase and increases blood flow to the follicle — was layered on top of an androgen environment that was actively remodeling those follicles.

The honest read is that this trial is excellent evidence that topical minoxidil does something real to facial hair, and moderate evidence about how much it will do for any given person. That is still a meaningful upgrade. It is not the "proof minoxidil grows beards" headline that will circulate.

If you are a trans man reading this

This trial was designed for you, which is unusual, and worth saying plainly. Alongside the density numbers, quality-of-life scores improved markedly in the minoxidil group — median Dermatology Life Quality Index fell from 5 to 1.5, against 4 to 3 in the placebo group — and satisfaction was substantially higher. The authors framed 3% topical minoxidil as an effective, well-tolerated adjunct to hormone therapy rather than a replacement for it.

The practical implication is about timing. If facial hair is still developing on hormone therapy, that is the window where the two mechanisms appear to stack most usefully. That is a conversation for the clinician managing your hormone therapy, not something to add unilaterally — minoxidil has real cardiovascular pharmacology and it belongs in the same medication review as everything else you are taking.

The safety finding is quietly important

Adverse events were minimal and comparable between the minoxidil and placebo arms over twelve weeks. That is reassuring, and it is the first properly controlled facial-application safety signal we have at this dose and duration.

It is also a twelve-week finding at 0.4 mL total daily on a defined area. It does not license open-ended, high-volume, whole-face application for years. Facial skin absorbs more readily than scalp skin, and minoxidil was originally an oral antihypertensive — the systemic pharmacology is not hypothetical.

What actually changes for you

• 3% is the studied concentration for facial use. Both the 2016 and 2026 trials used 3%. The 5% products on shelves are formulated and tested for scalp. That does not make 5% wrong, but you should know you are extrapolating.
• Twice daily was the protocol. Once-daily facial application has not been tested against placebo in a trial of this quality.
• Twelve weeks produced measurable change. Not visible-across-the-room change — measurable-by-dermoscope change. Set the expectation accordingly.
• The mustache is the strongest responder. If you are prioritizing coverage, that is where the data is best.
• Nobody has run this trial in cisgender men with modern methodology. That gap is the single most useful study anyone in this field could run next.

The bottom line

The evidence base for facial minoxidil went from one small photographic study to one small photographic study plus one well-run dermoscopy trial. That is real progress and it should increase your confidence that the drug does something.

It should not increase your confidence about your personal outcome, because the population studied had an androgen environment most readers do not share. Treat the mechanism as established and the magnitude as unknown, apply to the mustache area if you are choosing where to start, and have the conversation with a prescriber rather than a forum.